Device, systems and methods for evaluation of hemostasis

ABSTRACT

Provided are devices, systems and methods for evaluation of hemostasis. Also provided are sound focusing assemblies.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos.61/443,088, filed on Feb. 15, 2011, which is incorporated by referenceherein in its entirety.

ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under Grant Nos.R43-HL103030 and R44-DK085844 awarded by the National Institutes ofHealth. The Government has certain rights in the invention.

TECHNICAL FIELD

The present application relates to devices, systems and methods forevaluating hemostasis in a subject by analysis of a test sample from thesubject to determine one or more indices of hemostasis.

BACKGROUND

Hemostasis, the physiological control of bleeding, is a complex processincorporating the vasculature, platelets, coagulation factors(FI-FXIII), fibrinolytic proteins, and coagulation inhibitors.Disruption of hemostasis plays a central role in the onset of myocardialinfarction, stroke, pulmonary embolism, deep vein thrombosis andexcessive bleeding. Consequently, in vitro diagnostics (IVD) arecritically needed to quantify hemostatic dysfunction and directappropriate treatment. This need is particularly acute during cardiacsurgeries requiring cardiopulmonary bypass (CPB), where post-surgicalbleeding is a common complication requiring transfusion of bloodproducts.

Existing IVDs include endpoint biochemical assays, platelet aggregationassays, and clot viscoelastic measurement systems. Endpoint biochemicalassays such as the prothrombin time (PT) and the partial thromboplastintime (PTT) are widely used to assess coagulation. However, these testsmeasure only a part of the hemostatic process and operate undernon-physiological conditions incorporating only the function of plasma.As a result of these limitations, complications such as postoperativebleeding often occur despite normal perioperative PT and PTTmeasurements.

Activated clotting time (ACT) is an endpoint assay that is most oftenapplied in support of CPB. This assay applies strong initiation of thesurface activation (intrinsic) pathway to quantify heparinization.Limitations of the ACT include its disregard for platelet function,lysis, and coagulation kinetics along with the use of large aliquots ofwhole blood (WB) (generally 2 mL) and moving mechanical parts. For thesereasons, the ACT is used for rapid assessment of heparinization andassociated protamine reversal with limited utility for additionalapplications.

Platelets play a crucial role in the progression of coagulation andquelling arterial bleeding. Furthermore, the modern cell-based theory ofhemostasis recognizes that platelets play a modulating role incoagulation. Platelet function is monitored clinically via both centrallab assays and point of care (POC) tests, which use anticoagulated WB.Both approaches are limited in that they use platelet aggregation as aproxy for overall platelet function. Furthermore, disabling coagulation,these methods neglect the interaction between platelets and thecoagulation cascade.

Techniques that monitor the viscoelastic properties of WB, such asthromboelastography (TEG) and rotational thromboelastometer (ROTEM),circumvent many of the limitations of endpoint biochemical assays andplatelet aggregation assays by measuring the combined effects of allcomponents of hemostasis. TEG has been shown to diagnosehyperfibrinolysis in bleeding patients, indicate transfusionrequirements better than standard biochemical assays, and reducetransfusion requirements during CPB when used with transfusionalgorithms. While these tests offer valuable clinical information, thedevices are typically complex to operate and difficult to interpret.Moreover, the TEG applies relatively large shear strains, whichtransgress the non-linear viscoelastic regime, thereby disrupting clotformation. For these reasons, the TEG sees very limited utility as a POCtest.

SUMMARY

Provided are devices, systems and methods for evaluation of hemostasis.For example, provided are sonorheometric devices for evaluation ofhemostasis in a subject by in vitro evaluation of a test sample from thesubject. An example device comprises a cartridge having a plurality oftest chambers each configured to receive a test sample of blood from thesubject. Each test chamber comprises a reagent or combination ofreagents.

A first chamber of the plurality comprises a first reagent or acombination of reagents that interact with the test sample of bloodreceived therein. A second chamber of the plurality comprises a secondreagent or combination of reagents that interact with the test sample ofblood received therein. The first and second chambers are configured tobe interrogated with sound to determine a hemostatic parameter of thetest samples.

The example device can further comprise a third chamber having a thirdreagent or combination of reagents that interact with the test sample ofblood received therein and a fourth chamber having a fourth reagent orcombination of reagents that interact with the test sample of bloodreceived therein. The third and fourth chambers are also configured tobe interrogated with sound to determine a hemostatic parameter of thetests samples. Example reagents are selected from the group consistingof kaolin, celite, glass, abciximab, cytochalasin D, thrombin,recombinant tissue factor, reptilase, arachidonic acid (AA), adenosinediphosphate (ADP), and combinations thereof. Optionally, the reagentsare lyophilized prior to interacting with the test samples.

The example devices can be used in a system comprising a transducer fortransmitting ultrasound into one or more chamber and for receivingreflected sound from the chamber and the test sample therein. The systemcan further comprise at least one processor configured to determine ahemostasis parameter from the received sound. The parameters areoptionally selected from the group consisting of TC1, TC2, clotstiffness, clot formation rate (CFR), TL1 and TL2. The processor isoptionally further configured to determine an intrinsic pathwaycoagulation factors index, an extrinsic pathway coagulation factorsindex, a platelets index, a fibrinogen index, and a fibrinolysis indexvalue. The intrinsic and extrinsic coagulation factors are optionallycombined to form a coagulation factors index.

Also provided are sonorheometric methods for evaluation of hemostasis ina subject, comprising a cartridge having at least two test chambers.Each test chamber comprises a reagent or combination thereof. Blood fromthe subject is introduced into the test chambers to mix with thereagents and ultrasound is transmitted into each test chamber. Soundreflected from the blood reagent mixture in the test chamber is receivedand processed to generate a hemostasis parameter. The parameters areoptionally selected from the group consisting of TC1, TC2, clotstiffness, clot formation rate (CFR), TL1 and TL2. The disclosed methodscan further include determining an intrinsic pathway coagulation factorsindex, an extrinsic pathway coagulation factors index, a plateletsindex, a fibrinogen index, and a fibrinolysis index value. The intrinsicand extrinsic coagulation factors are optionally combined to form acoagulation factors index. The reagents or combinations thereof areoptionally lyophilized prior to mixing with the blood.

Further provided are sound focusing assemblies. An example soundfocusing assembly includes a rigid substrate permeable by sound and anelastomeric couplant permeable by sound. The elastomeric couplant ispositioned relative to the rigid substrate to create an interfacebetween the elastomeric couplant and the rigid substrate, wherein theinterface focuses sound transmitted through the assembly.

These and other features and advantages of the present invention willbecome more readily apparent to those skilled in the art uponconsideration of the following detailed description and accompanyingdrawings, which describe both the preferred and alternative embodimentsof the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-G are schematic illustrations of an example cartridge forevaluating hemostasis.

FIG. 2 is a schematic illustration of biological fluid pathways of theexample cartridge of FIGS. 1A-G.

FIG. 3 is a schematic illustration of an example processing system foruse with the example cartridge of FIGS. 1A-G.

FIG. 4 is a schematic illustration of a portion of a system forevaluating hemostasis.

FIG. 5 is a schematic illustration of a portion of a system forevaluating hemostasis.

FIG. 6A is a schematic illustration showing N acoustic pulses are sentinto a blood sample to generate a force. The resulting deformation canbe estimated from the relative time delays between the N returningechoes.

FIG. 6B is a graph showing example displacement curves generated withina blood sample. As blood clots, reduced displacement is observed.

FIG. 6C is a graph showing displacements combined to form graphs ofrelative stiffness, which characterize the hemostatic process. Theparameters described in panel are estimated from parameters found byfitting a sigmoidal curve.

FIG. 7 is a flow diagram illustrating an example method to estimatehemostasis parameters.

FIGS. 8A-D are schematic illustrations of an example cartridge forevaluating hemostasis.

FIGS. 9A-C are schematic illustrations of portions of a system forevaluating hemostasis including pressure control mechanisms.

FIGS. 10A and 10B are schematic illustrations of an example sample flowpattern for use with the described devices and systems and of an examplecartridge for evaluating hemostasis.

FIG. 11 is a graph showing data of heating of blood within an examplecartridge for evaluating hemostasis.

FIGS. 12A-C are schematic illustrations of example sound focusingmechanisms.

DETAILED DESCRIPTION

The present invention now will be described more fully hereinafter withreference to specific embodiments of the invention. Indeed, theinvention can be embodied in many different forms and should not beconstrued as limited to the embodiments set forth herein; rather, theseembodiments are provided so that this disclosure will satisfy applicablelegal requirements.

As used in the specification, and in the appended claims, the singularforms “a,” “an,” “the,” include plural referents unless the contextclearly dictates otherwise.

The term “comprising” and variations thereof as used herein are usedsynonymously with the term “including” and variations thereof and areopen, non-limiting terms.

As used throughout, by a “subject” is meant an individual. The subjectmay be a vertebrate, more specifically a mammal (e.g., a human, horse,pig, rabbit, dog, sheep, goat, non-human primate, cow, cat, guinea pigor rodent), a fish, a bird or a reptile or an amphibian. The term doesnot denote a particular age or sex.

FIGS. 1A-G illustrate an example cartridge 100 for use in evaluation ofhemostasis in a subject. The cartridge 100 includes a front surface 101and a rear surface 126. FIG. 1A shows a front view of the cartridge 100and the corresponding front surface 101. The cartridge includes an inlet102, also referred to herein as an inlet port or entry port, such as anipple, thought which a biological sample from the subject can beintroduced into the cartridge. Optionally, a blood sample from thesubject is introduced into the cartridge at the inlet 102. Anotherbiological sample that may be introduced for analysis is plasma. Theinlet 102 is in fluid communication with a channel 202, which is shownin FIG. 2, and which directs the biological sample to other portions ofthe cartridge as described herein.

The cartridge further includes a port 106 for applying a vacuum to thecartridge. When a vacuum is applied at the port 106, the biologicalfluid introduced at the inlet 102 into the channel 202 the fluid ispropelled along the channel 202 towards the port 106.

As shown in FIG. 2, in moving between the inlet 102 and the port 106,the biological fluid, or a portion thereof, moves along the channel 202,into the channel 204, the channel 206, and along the channels 208, 210,212 and 214. Each of channels 208, 210, 212 and 214 are in fluidcommunication with a test chamber, also referred to herein, for example,as a, chamber, well or test well or the like. For example, asillustrated in FIG. 2, channel 208 is in fluid communication with a testchamber 116, channel 210 is in fluid communication with a test chamber114, channel 212 is in fluid communication with a test chamber 112, andchannel 214 is in fluid communication with a test chamber 110.

Referring again to FIG. 1, each test chamber comprises an open space 124defined by a portion of the rear surface 126. FIG. 1B shows across-sectional illustration through test chamber 116 taken across theline B-B of FIG. 1A. FIG. 1C shows a cross-sectional illustration takenacross the line C-C of FIG. 1A. FIG. 1F shows an expanded view of thecircled portion of FIG. 1B. Moreover, FIG. 1D shows a cross-sectionalillustration across the line D-D of FIG. 1A, which illustrates the openspace of each of the four test chambers.

Each test chamber is configured to accept a quantity of the biologicalfluid into the open space. In reference to test chamber 116, illustratedin detail in FIG. 1F, a portion of the biological fluid introduced atthe inlet 102 moves through the channels 202, 204 and 214 and into theopen space 124 of the test chamber 116.

The biological fluid can also exit each respective test chamber andcontinue along an exit channel 130 towards the port 106. Thus, fluidintroduced at the inlet 102 flows under vacuum through the devicechannels and into the test chambers. From each test chamber (110, 112,114, 116), the biological fluid continues to flow along exit channelstowards the vacuum.

Proximate the port 106 each exit channel may direct the flowingbiological fluid into a hydrophobic filter at location 222, 220, 218 and216 respectively. The filters or filter prevents movement of thebiological fluid out of the cartridge 100 at the port 106. Because thevolume of the channels and the test chamber are fixed, the vacuum canpull the biological fluid into the cartridge until the channels and eachtest chamber is filled with the biological fluid.

Pressure can be controlled within the cartridge 100 to, for example,manage flow rate within the consumable 100 and to mitigate reliabilityissues related to possible user misuse. To measure the properties of atarget biological sample, such as a blood sample, a user of thehemostasis system optionally attaches a blood filled syringe to thecartridge 100 unit. There exists the possibility that the user of thehemostasis system 300 (see FIG. 3) could attempt to inject the contentsof the applied syringe into the cartridge 100 manually, instead ofallowing the device to automatically aspirate the sample. This actionmay lead to measurement or system error. A pressure management device inthe consumable flow path is used to prevent this user action.

Inadequate mixing of the biological sample with the reagents describedherein may result in variation of hemostasis measurements. Rapidlyaspirating the blood sample is optionally used to provide increasedmixing of the reagents with the biological sample, such as a bloodsample. This is optionally achieved by creating a pressure differentialbetween the cartridge and the aspirating mechanism of the hemostasissystem.

In this regard, FIGS. 9A-C illustrate three example configurations thatcan be used to control the pressure differential between the cartridgeand the aspirating mechanism and can therefore be used to achievedesired levels of mixing and reduce user errors.

FIG. 9A schematically illustrates an example system 900 for controllingpressure in a cartridge 100. The cartridge includes four test chambers(110, 112, 114 and 116). Each test chamber optionally includes a reagentand operation of the system causes a biological sample to enter one ormore test chamber. The example system 900 includes a two way pump 908which operates to aspirate a biological sample, such as a blood sample.For example, a blood sample can be aspirated into the cartridge from asample container 902. The pump 908 is in fluid communication with thecartridge 100 and therefore activation of the pump can be used to movethe biological sample through the cartridge 100. A pressure transducer904 is in communication with the pump that measures the gauge pressuredrawn by the pump 908. A solenoid actuated valve 906 operates to blockflow downstream of the pump allowing gauge pressure to build. Thesolenoid may be selectively actuated to rapidly expose the pressuregradient to the cartridge. The sample is allowed to progress through thecartridge and is optionally collected in a sample container 910.

FIG. 9B schematically illustrates another example system 920 forcontrolling pressure in a cartridge 100. The cartridge includes fourtest chambers (110, 112, 114 and 116). Each test chamber optionallyincludes a reagent and operation of the system causes a biologicalsample to enter one or more test chamber. The example system 920includes a two way pump 908 which operates to aspirate a biologicalsample, such as a blood sample. For example, a blood sample can beaspirated into the cartridge from a sample container 902. The pump 908is in fluid communication with the cartridge 100 and thereforeactivation of the pump can be used to move the biological sample throughthe cartridge 100. A pressure activated membrane 912 is positionedeither upstream or downstream of the cartridge 100 from the pump 908.The membrane 912 is configured to rupture at a predetermined cartridgegauge pressure thereby controlling the pressure at which the sample isdrawn through the cartridge. The sample is allowed to progress throughthe cartridge and is optionally collected in a sample container 910.

FIG. 9C schematically illustrates another example system 930 forcontrolling pressure in a cartridge 100. The cartridge includes fourtest chambers (110, 112, 114 and 116). Each test chamber optionallyincludes a reagent and operation of the system causes a biologicalsample to enter one or more test chamber. The example system 930includes a two way pump 908 which operates to aspirate a biologicalsample, such as a blood sample. For example, a blood sample can beaspirated into the cartridge from a sample container 902. The pump 908is in fluid communication with the cartridge 100 and thereforeactivation of the pump can be used to move the biological sample throughthe cartridge 100. A closed loop actuated valve 916 contains an internalpressure control mechanism and is used to block flow downstream from thepump allowing gauge pressure to build until a valve pressure setpoint.Once gauge pressure setpoint is reached the valve 916 deploys therebyexposing the cartridge to a desired pressure gradient. The sample isallowed to progress through the cartridge and is optionally collected ina sample container 910.

The level of sample in each chamber can also be monitored. For example,as shown in FIGS. 8A-8D, the level of fluid in each chamber can bemonitored optically. FIG. 8A is a schematic illustration of an exampleconsumable cartridge placed in an example hemostasis evaluation system.FIG. 8B is a schematic illustration of a cross section taken across lineB-B of FIG. 8A. FIG. 8C is an expanded schematic illustration of thecircled portion of FIG. 8B. FIG. 8D is a schematic illustration of anexample consumable cartridge.

Whether a desired level has been reached in a given chamber can beindicated by a LED or other visual indicator. Employing a single lightbeam from an LED emitter 802 reflecting off the chamber at a blooddetection target reservoir 224, which is then detected by a detector 800can be optionally used to optically monitor chamber fluid level.

For example, blood entering a test chamber reduces reflection of lightoriginating from an emitter 802 located alongside the detector 800, andpointed at the test chamber. A dual beam approach can be used wherebytwo sources of different wavelengths were reflected off the testchamber. Blood has a deep red color that can be differentiated bycomparing the red wavelength reflection to that of another colour.

The difference in intensity of the reflected red light alone issufficient to determine when blood has entered a chamber. The red lightintensity reflected from the test chamber containing blood was aboutone-half that of the well containing air, and about two-thirds of thatfrom the well containing water.

To control the temperature of the biological sample entering the testchambers the cartridge 100 can comprise a heat exchanger incommunication with the channel 204. The heat exchanger can be used tomaintain, elevate or lower the temperature of the biological fluidbefore analysis in each test chamber. Optionally, the temperature ofbiological fluid for analysis in each test chamber is the same such thatcommon portion of the channel system, as shown in FIG. 2, is subject totemperature manipulation by the heat exchanger. Optionally, innon-pictured embodiments, the temperature of biological fluid enteringeach test chamber can be separately controlled.

For example, to heat the biological fluid, it can be passed through thechannel 204 through a polystyrene labyrinth held against a copper block.The copper block can be thin (for example under 2 mm) and sized justlarger than the labyrinth to minimize the thermal mass. A thermistor canbe embedded in the block so that a control circuit could maintain asteady set temperature in the block. A heater is used that optionallycomprises two Watlow® (St. Louis, Mo.) serpentine foil heating elementsbonded to a flexible kapton plastic substrate, and the interface betweenthe block and the heater can be a thin layer of silicone heatsinkcompound.

Various flow rates, for example, up to and including 5.99 ml/min or 6.0ml/min can be used, and power input to the heater can be variedoptionally between 8 and 16 Watts. Blood or other biological fluid canbe heated in the cartridge from ambient temperature (approximately 20°C.) to 37° C. at a nominal flow rate of 6 ml/min, which is fast enoughto fill the cartridge in 20 seconds. The surface area of the labyrinthused was less than 8 cm².

Physiologically, the process of coagulation is highly dependent on thetemperature at which it takes place. Under normal conditions,coagulation occurs at body temperature (37° C.), which is optimal forthe proper enzymatic action of the clotting factors in the cascade.

Blood can be warmed from its incoming temperature, ranging between 18°C. and 37° C., to an arbitrary or desired temperature, such as bodytemperature, of 37° C. by passing through a serpentine channel in closeproximity to a heater block. To accomplish the heating in a short timeover a short path the block can be warmed to almost 60° C. when theincoming blood is at the lower end of its temperature range. Thetemperature of the blood can also be measured and the heater block canoptionally be adjusted to a temperature, ranging from 40° C. to 58° C.

To measure the temperature a sensor can be incorporated in the system300 (FIG. 5) or in the cartridge. Optionally, a thermistor orthermocouple placed in physical contact with the cartridge or blood andan IR thermometer is pointed at the cartridge or blood. In either casethe cartridge may incorporate a small well through which the incomingblood passes, rather than having direct contact with the blood. When thecartridge's material (polystyrene) is thin and the blood is kept movingthrough the well, then the larger heat capacity of the blood ensures thewell's wall temperature is close to that of the blood. Optionally, awindow allowing the passage of IR is used. The window can comprise athin layer (e.g. 20 um or less) of polyethylene or polystyrene.

Temperature changes can occur in the body due to fever or in hospitalsettings such as the emergency room (ER) or operating room (OR). Traumapatients arriving at the ER are treated with large volumes ofintravenous saline, which lowers body temperature to as much as 17° C.In the OR, patients undergoing cardiac bypass surgeries (CPB) have theirentire blood volume pass through a lung-heart machine, which also lowersblood temperature and can adversely affect coagulation. Also, if thereis a lag of time between the time of blood draw and the measurement, thetemperature of blood is given time to change.

Styron® 666 (Styron Inc. Berwyn, Pa.) polystyrene and the microfluidicheat exchanger channel 204 allows a blood sample to be warmed by acopper block outside of the cartridge that is kept at a constant 37° C.When a sample enters the cartridge at temperatures substantially lowerthan 37° C., it is optionally desirable to use a cartridge modified toallow for more rapid heating of the biological sample. For example, in amodel that simulates the temperature changes over time of blood enteringthe polystyrene cartridge at 17° C., Styron® 666 was found to reduceability to heat blood and the blood exiting the heat exchanger did notreach 37° C. These shortcomings of Styron® 666 are due to its relativelylow thermal conductivity. When more rapid or efficient heating of thebiological sample is desired that is possible through Styron® 666, thecartridge can include materials with higher thermal conductivity thanStyron® 666. For example, a thermally conductive polymer (E1201®) fromCool Polymers Inc. (North Kingstown, R.I.) with improved thermalconductivity properties can be used. This polymer can form a portion ofthe cartridge between the heating block and the channel 204. By usingthis polymer in a portion of the cartridge between the heating block andsample, the sample can be more efficiently heated. For example, FIG. 11shows that in a cartridge comprising this material blood entering theheat exchanger at 17° C. reaches 37° C. within 15 seconds.

Cartridges optionally include both materials, E1201® and Styron® 666, inorder to improve the heat transfer to the sample with E1201® on theheated side while maintaining flow visibility on the other side of theconsumable with the Styron® 666. Another alternative is to use E1201® asan insert that fits over the copper heater and into a chassis made outof Styron® 666. This is optionally accomplished by overmolding theseparate pieces into one single piece or affixing the E1201® to theStyron® chassis by means such as laser, ultrasonic or RF welding.Changing the geometry of the E1201® insert to fit into the largerchassis as a puzzle piece can further improve assembly of the separateparts and help seal the microfluidic flow chambers.

It may also be desirable to cool the biological fluid in the cartridge.In these example, and similar to when heating is desired, the cartridgecan include materials with higher thermal conductivity than Styron® 666.For example, the thermally conductive polymer (E1201®), described above,with improved thermal conductivity properties can be used. This polymercan form a portion of the cartridge between a cooling device, such as apeltier cooling device, and the channel 204. Using this polymer in aportion of the cartridge between the cooling device and sample, thesample can be efficiently cooled.

Each test chamber can comprise one or more reagents useful in theanalysis of one or more indices of hemostasis. Optionally, the reagentsare lyophilized. Optionally, one or more lyophilized bead type reagentis used. For example, the lyophilized bead can be a LyoSphere® producedby BioLyph (Minnetonka, Minn.). A self-contained lyophilized bead is aformat that allows for immunochemical and clinical chemistry reagentsrequiring two or three components that are incompatible as liquidsbecause of their pH level or reaction to one another to coexistcompatibly. Because such lyophilized beads are stable and nonreactive,chemicals can be packaged together in the same test chamber.

To produce lyophilized reagents, a lyophilizer device can be used. Forexample, the reagent for a given test chamber can be frozen to solidifyall of its water molecules. Once frozen, the product is placed in avacuum and gradually heated without melting the product. This process,called sublimation, transforms the ice directly into water vapor,without first passing through the liquid state. The water vapor givenoff by the product in the sublimation phase condenses as ice on acollection trap, known as a condenser, within the lyophilizer's vacuumchamber. Optionally, the lyophilized product contains 3% or less of itsoriginal moisture content. The lyophilized product, which may be apellet, can then be positioned in each test chamber. Once placed in atest chamber, the test chamber can be sealed to prevent unwantedrehydration of the product.

To locate the lyophilized reagents in the test chambers, the componentscan first be lyophilized and then the resulting lyophilized product canbe placed in the test chambers. Using UV cure epoxy glue or a weldingprocess (such as ultrasound or RF welding), the lens assembly is sealedover each of the test chambers. The assembled cartridge can be sealed ina vapor proof barrier (e.g. a bag) and the vapor barrier can be sealedto preserve the dehydrated nature of the product in the test chambers.When ready for use, the cartridge can be removed from the bag or vaporbarrier and placed into an analysis system 300, which is described infurther detail below.

Anti-static treatment of plastic cartridges is optionally used with thelyophilized reagents. Lyophilized reagents are inherently devoid ofwater, granting them significant electrical insulation.

Materials that are electrical insulators more readily build up staticcharge than materials that act as electrical conductors. This can createproblems with process control when assembling the cartridges and loadingthe reagents. Since the cartridges are optionally made from anelectrically insulating material (polystyrene, for example), it is notlikely to dissipate a static charge build up within the lyophilizedreagents. As a result, lyophilized reagents can statically adhere to theinterior walls of the consumable. In order to prevent this fromoccurring, three techniques are optionally implemented to remove staticbuild-up.

Air ionization is a method that passes directed, ionized air over atarget material to neutralize residual static charge on the materialsurface. Directing ionized air at one or more cartridge test chamberand/or the reagents during the assembly process improvesmanufacturability by reducing the adherence of the reagent bead to thecartridge test chambers.

A second method implements cartridge construction using a plasticmaterial that exhibits significantly more conductivity than standardinjection molding materials. RTP PermaStat® (Winona, Mass.) plastics arean example of such materials. The use of this material for the cartridgereduces the adhesion of the lyophilized reagents to the cartridge testchamber walls.

Third anti-static, liquid sprays are used to temporarily create adust-free coating on optical lenses and equipment. These sprays reducestatic charge on the target surface and are useful for static reductionduring the cartridge assembly process.

When the lyophilized reagents are exposed to the fluid sample, they cangenerate foam that floats at the surface of the sample in the testchambers. As illustrated in FIGS. 10A and B, the consumable cartridge1002 optionally comprises a fluidic circuit 202 that delivers the samplefrom an external vessel, such as a syringe or vacutainer, into one ormore test chambers (110, 112, 114, 116) were measurements are performed.

FIG. 10A shows an example fluidic circuit that can be implemented in aconsumable cartridge 1002. This circuit includes an entry port 102, achannel 202, at least one test chamber (110, 112, 114, 116), a filter1004 and an exit port 1006. The biological sample can be deliveredwithin the chamber by applying a vacuum at the exit port, with thefilter allowing air to escape but stopping the fluid. A variety ofdifferent reagents can be placed within the test chamber, for example,as described throughout. In order to generate accurate measurements, thereagents are mixed within the sample before testing is initiated. Forexample, ultrasound emitted into the test chambers can be used to mixthe reagents with the sample as described below.

As shown in FIGS. 10A and 10B, to improve mixing of the foam, abiological fluid sample can flow through the channel 202, which entersthe test chamber at the side on a tangent to the chamber. Furthermore,the change in channel diameter from large to small increases the flowvelocity (conservation of flow rate) at the entrance to the testchamber. This high flow velocity, in collaboration with gravity, helpsgenerate a re-circulating rotational flow pattern that improves mixingand reagent dispersion with the sample. As the flow enters from theside, it causes any formed foam to be pulled into the flow stream andpushed below the surface.

FIG. 10B shows a flow pattern implemented in a consumable cartridgedesigned for injection molding. The fluidic circuit has been repeatedfour times in order to deliver the sample and mix reagents in fourdifferent test chambers. The circuit presented in FIG. 10B also includesa serpentine heat exchanger to adjust the temperature of the incomingsample to a desired level.

Reagents are mixed with the sample before testing is initiated. Mixingof the reagents can be accomplished using passive and/or activemechanisms. Passive methods include, for example, the use of serpentinechannels and embedded barriers to create flow turbulence. Active methodsinclude, for example, magnetic beads, pressure perturbation, andartificial cilia. The consumable cartridge contains a lens that focusesultrasound energy within the sample that can be used to generatestreaming and mixing. The lens, also referred to herein as a lensassembly, or sound focusing assembly, is designed using a soft material,such as a thermoplastic elastomer 134, in conjunction with a rigidsubstrate 132, such as polystyrene. This combination provides a dryultrasound coupling that does not require the use of any fluid or gelcouplant. Note that the same lens and ultrasound driver used forhemostasis measurement can be used in this matter to provide mixing.Increasing acoustic energy for mixing can be delivered by, for example,increasing pulse length, pulse amplitude or pulse repetition frequency.

Mixing can also be provided by a variable magnetic field applied by aseries of coils placed outside a test chamber or each test chamber. Asmall magnetic bead or magnetic stirrer can be placed within a testchamber and when the fluid sample enter the chamber, the current acrossthe coils can be modulated in order to generate a variable magneticfield. This generates motion of the magnetic bead or magnetic stirrerwhich in turns generates mixing of the sample with the reagent.

The exposure of blood to surface proteins, such as in the case ofcollagen or von Willebrand factor (vWF) on damaged blood vessel walls isan essential part of the coagulation process. These proteins not onlycontribute to the clotting cascade but also modulate several stepsleading to clot formation and hemostasis.

Although exposure to these proteins is essential to the coagulationcascade, standard point-of-care (POC) coagulation assays and devicesfail to take this interaction into account. Optionally, the test well(s)and/or channel(s) of a consumable cartridge, such as those describedherein, are coated with such surface proteins for the measurement ofcoagulation within a POC medical device.

The use of surface protein coatings includes collagen, vWF, fibronectinand any other molecule that modulates coagulation such as fibrinogen andthrombin. A layer of protein on a substrate (glass, polystyrene,polypropylene) creates binding sites that allow the mediation ofreceptor-ligand interactions between the substrate and other biologicalmaterials such as blood in a manner that improves the assessment ofcoagulation or provides new testing information.

The interior surfaces of a consumable cartridge can be coated using forexample: (1) a layer of such proteins by covalent binding using linkermolecules, (2) covalent binding using photochemistries or (3) simpleprotein adsorption. Linker molecules such as streptavidin or avidin andbiotin can be used for this purpose. With linker molecules, the surfaceof any interior portion of the cartage that will be exposed to thebiological sample is biotinylated (coated with a layer of biotin) usingcommercially available biotin that is conjugated to a reactive groupthat non-specifically and covalently binds with the substrate. Asolution with a high concentration of streptavidin or avidin, which havehigh affinity for biotin, is added to create a layer ofstreptavidin/avidin bound biotin. Addition of biotinylated protein(collagen, vWF, fibronectin, thrombin, fibrinogen) then creates a layerof protein bound to the test well surface that specifically affectscoagulation through interactions with plasma proteins and platelets.

Protein adsorption can be accomplished by filling the wells with ahighly concentrated protein solution. Adsorption to the plastic surfacetakes place almost immediately depending on temperature, ph, surfacecharges, surface morphology and chemical composition. The solution canthen be removed and the surface air dried. Brushing a highlyconcentrated protein solution on the surface of the wells or dipping thewells into such a solution will accomplish the same purpose.

The concentration of molecules in the solutions used for coating,whether using linker proteins or adsorption, can be changed to modulatethe amount of protein that binds the substrate and, thus, modulate theeffects on the coagulation cascade in a way that is relevant tophysiology and hemostasis.

Referring again to FIG. 1F, to seal each test chamber, e.g. test chamber116, a lens assembly 131 includes a rigid substrate 132 and a couplant134 that can be positioned at the back end of each test chamber. Eachcouplant 134 comprises an elastomeric material. Optionally, theelastomeric material is a thermoplastic elastomer (TPE). Exampleelastomeric materials optionally include, Dynaflex D3202, Versaflex OM9-802CL, Maxelast S4740, RTP 6035. Optionally the couplant isover-molded to the rigid substrate.

Between each couplant 134 and the open space of each test chamber is arigid substrate 132. The rigid substrate and the couplant form aninterface that focuses ultrasound transmitted (e.g. lens assembly) by anultrasonic transducer into the chamber's open space and onto anybiological fluid and/or reagents in the chamber. The rigid substrate ofthe lens can comprise a material which allows sound to pass and that canact to focus ultrasound at some level within the space. Optionally, therigid substrate comprises a styrene, such as, for example Styrene® 666.

The lens assembly may be glued or welded to the surface 101 to securethe lens in place in an orientation that allows the desired focusing ofsound. Alternatively, the lens assembly is optionally manufacturedtogether with the surface 101. In this regard, the rigid substrate 132can be molded with the surface 101 and the couplant 134 can beovermolded on the rigid substrate. A wide variety of materials can beused to construct the device. For example, plastics can be used forsingle use, disposable cartridges.

Each test chamber (116, 114, 112 and 110) can have a lens assemblypositioned over the large opening of each chamber's open space. In thisway, each chamber can be separately interrogated by focused ultrasound.

When placed in the analysis system 300, the couplant 134 can be placedin acoustic communication with a transducer for supplying ultrasoundthrough the lens assembly and into a test chamber. Optionally, anintermediate layer of an acoustically permeable material is positionedbetween an ultrasonic transducer and the couplant. For example, andintermediate layer or block of Rexolite® can be used. The intermediatelayer can be forced against the couplant and can be in acoustic contactwith the transducer.

Sound generated by a transducer passes through the intermediate layer,through the couplant, through the rigid substrate, and is focused withinthe biological sample and reagent in the test chamber. Some of the sounddirected into chamber contacts the distal interior surface 111 of thetest chamber, which is defined by the surface 126. Optionally, thesurface is polystyrene. The distal interior surface has a know geometryand is positioned at a know distance from the ultrasound source. Thedistal interior surface 111 is used as a calibrated reflector, which isused to estimate the speed of sound and attenuation of sound in a testchamber at base line and during the process of clot formation and clotdissolution. These measurements can be used, for example, to estimatehematocrit of the subject along with the indexes of hemostasis. Thesound generated by the transducer can be focused within the biologicalsample in a test chamber using a parabolic mirror that is coupled to thebiological sample using an elastomer.

FIG. 12A illustrates an example geometry for a parabolic mirror that canbe used to focus sound into one or more test chamber, wherein f(x,y) isthe shape of the focusing reflector, z₀ is the height of the reflectorabove the active element at the origin, and (x_(f), y_(f), z_(f)) is thecoordinate of the focal point. The focusing reflector is defined by acurve which is equidistant from the emitting point on the activeacoustic element and the focal point. This can be expressed as:d=f(x,y)+√{square root over ((x _(f) −x)²+(y _(f) −y)²+(z _(f)−f(x,y))²)}{square root over ((x _(f) −x)²+(y _(f) −y)²+(z _(f)−f(x,y))²)}{square root over ((x _(f) −x)²+(y _(f) −y)²+(z _(f)−f(x,y))²)}  (1)Where d is the total distance from the face of the acoustic source tothe focus. If the distance is set from the origin to the reflector asz₀, then the total path-length is:d=z ₀+√{square root over (x _(f) ² +y _(f) ²+(z _(f) −z ₀)²)}  (2)The shape of the reflector can be determined by solving for f(x,y) asfollows:

$\begin{matrix}{\mspace{20mu}{d = {{f\left( {x,y} \right)} + \sqrt{\left( {x_{f} - x} \right)^{2} + \left( {y_{f} - y} \right)^{2} + \left( {z_{f} - {f\left( {x,y} \right)}} \right)^{2}}}}} & (3) \\{\mspace{20mu}{{d - {f\left( {x,y} \right)}} = \sqrt{\left( {x_{f} - x} \right)^{2} + \left( {y_{f} - y} \right)^{2} + \left( {z_{f} - {f\left( {x,y} \right)}} \right)^{2}}}} & (4) \\{\mspace{20mu}{\left( {d - {f\left( {x,y} \right)}} \right)^{2} = {\left( {x_{f} - x} \right)^{2} + \left( {y_{f} - y} \right)^{2} + \left( {z_{f} - {f\left( {x,y} \right)}} \right)^{2}}}} & (5) \\{{d^{2} - {2{{df}\left( {x,y} \right)}} + {f^{2}\left( {x,y} \right)}} = {\left( {x_{f} - x} \right)^{2} + \left( {y_{f} - y} \right)^{2} + z_{f}^{2} - {2z_{f}{f\left( {x,y} \right)}} + {f^{2}\left( {x,y} \right)}}} & (6) \\{\mspace{20mu}{{d^{2} - {2{{df}\left( {x,y} \right)}}} = {\left( {x_{f} - x} \right)^{2} + \left( {y_{f} - y} \right)^{2} + z_{f}^{2} - {2z_{f}{f\left( {x,y} \right)}}}}} & (7) \\{\mspace{20mu}{{{2z_{f}{f\left( {x,y} \right)}} - {2{{df}\left( {x,y} \right)}}} = {\left( {x_{f} - x} \right)^{2} + \left( {y_{f} - y} \right)^{2} + z_{f}^{2} - d^{2}}}} & (8) \\{\mspace{20mu}{{{f\left( {x,y} \right)}\left( {{2z_{f}} - {2d}} \right)} = {\left( {x_{f} - x} \right)^{2} + \left( {y_{f} - y} \right)^{2} + z_{f}^{2} - d^{2}}}} & (9) \\{\mspace{20mu}{{f\left( {x,y} \right)} = \frac{\left( {x_{f} - x} \right)^{2} + \left( {y_{f} - y} \right)^{2} + z_{f}^{2} - d^{2}}{2\left( {z_{f} - d} \right)}}} & (10)\end{matrix}$

If z₀ is set, then the equation 2 above can be evaluated and substitutedinto equation 10 above to yield an equation for the surface of thereflector. The reflector is a parabolic section. Example parameters areoptionally an 8 mm aperture with a focus at 16 mm laterally, 4 mm inrange and with an offset between the mirror and aperture of 0.5 mm. Adiagram of this geometry is shown in FIG. 12B. This geometry is usefulwhere the focusing mirror is placed within the system. The mirror canalso be placed within the cartridge. In this case, the focus isoptionally moved closer in the axial dimension, but further in thelateral dimension as shown in FIG. 12C.

The cartridge 100 can be positioned into pocket 302 of an analysissystem 300. As shown in FIG. 4, the pocket includes an actuator system402 for pressing the intermediate layer, such as Rexolite®, that isacoustically coupled to a transducer into contact with the couplant 134.In this way the pocket holds the cartridge in securely in place and inan orientation such that ultrasound can be focused into each testingchamber.

FIG. 5 shows further aspects of the cartridge 100 positioned in theanalysis system. The cartridge is positioned such that the intermediatelayer 504 is pushed into the couplant 134, which is in communicationwith the rigid substrate 132 of the lens assembly 131. Ultrasonicgenerating means 502, including at least one ultrasonic transducer arepositioned such that ultrasound is transmitted through the intermediatelayer, lens assembly, and into the test chamber.

At least a portion of the sound is reflected by the biological samplepositioned therein the chamber, and a portion of the sound transmittedinto the chamber can also be reflected from the chamber distal surface111. The reflected ultrasound can be received by the ultrasonictransducer and transmitted to the system for processing. Thus thecartridge and the analysis system 300 may be in communication such thatdata and other operational or processing signals may be communicatedbetween the cartridge and the analysis system.

A suitable analysis system 300 can therefore comprise one or moreprocessing devices. The processing of the disclosed methods, devices andsystems can be performed by software components. Thus, the disclosedsystems, devices, and methods, including the analysis system 300, can bedescribed in the general context of computer-executable instructions,such as program modules, being executed by one or more computers orother devices. Generally, program modules comprise computer code,routines, programs, objects, components, data structures, etc. thatperform particular tasks or implement particular abstract data types.For example, the program modules can be used to cause the transmissionof ultrasound having desired transmit parameters and to receive andprocess ultrasound to evaluate hemostasis indices of a sample from thesubject. The software can also be used to control the heating of thebiological sample using the heat exchanger and to monitor and indicatethe fill level of a given chamber. The processor can also be used toperform algorithms, to determine hemostatic indices and hematocrit. Insome examples, the software can be used to back-out determinedhematocrit from determined hemostatic indices. The determined hemostaticindices and hematocit can be displayed to a medical professional ormedical agent for the purpose of making medical decisions for a subject.

Thus, one skilled in the art will appreciate that the systems, devices,and methods disclosed herein can be implemented via a general-purposecomputing device in the form of a computer. The computer, or portionsthereof, may be located in the analysis system 300. The components ofthe computer can comprise, but are not limited to, one or moreprocessors or processing units, a system memory, and a system bus thatcouples various system components including the processor to the systemmemory. In the case of multiple processing units, the system can utilizeparallel computing.

The computer typically comprises a variety of computer readable media.Exemplary readable media can be any available media that is accessibleby the computer and comprises, for example and not meant to be limiting,both volatile and non-volatile media, removable and non-removable media.The system memory comprises computer readable media in the form ofvolatile memory, such as random access memory (RAM), and/or non-volatilememory, such as read only memory (ROM). The system memory typicallycontains data such as data and/or program modules such as operatingsystem and software that are immediately accessible to and/or arepresently operated on by the processing unit.

In another aspect, the computer can also comprise otherremovable/non-removable, volatile/non-volatile computer storage media.By way of example, a mass storage device, which can provide non-volatilestorage of computer code, computer readable instructions, datastructures, program modules, and other data for the computer. Forexample and not meant to be limiting, a mass storage device can be ahard disk, a removable magnetic disk, a removable optical disk, magneticcassettes or other magnetic storage devices, flash memory cards, CD-ROM,digital versatile disks (DVD) or other optical storage, random accessmemories (RAM), read only memories (ROM), electrically erasableprogrammable read-only memory (EEPROM), and the like.

Optionally, any number of program modules can be stored on the massstorage device, including by way of example, an operating system andsoftware. Each of the operating system and software, or some combinationthereof, can comprise elements of the programming and the software. Datacan also be stored on the mass storage device. Data can be stored in anyof one or more databases known in the art. Examples of such databasescomprise, DB2®, Microsoft® Access, Microsoft® SQL Server, Oracle®,mySQL, PostgreSQL, and the like. The databases can be centralized ordistributed across multiple systems.

In another aspect, the user can enter commands and information into thecomputer via an input device. Examples of such input devices comprise,but are not limited to, a keyboard, pointing device (e.g., a “mouse”), atouch screen, a scanner, and the like. These and other input devices canbe connected to the processing unit via a human machine interface thatis coupled to the system bus, but can be connected by other interfaceand bus structures, such as a parallel port, game port, an IEEE 1394Port (also known as a Firewire port), a serial port, or a universalserial bus (USB).

In yet another aspect, a display device 304, such as a touch screen, canalso be connected to the system bus via an interface, such as a displayadapter. It is contemplated that the computer can have more than onedisplay adapter and the computer can have more than one display device.For example, a display device can be a monitor, an LCD (Liquid CrystalDisplay), or a projector.

Any of the disclosed methods can be performed by computer readableinstructions embodied on computer readable media. Computer readablemedia can be any available media that can be accessed by a computer. Byway of example and not meant to be limiting, computer readable media cancomprise computer storage media and communications media. Computerstorage media comprise volatile and non-volatile, removable andnon-removable media implemented in any method or technology for storageof information such as computer readable instructions, data structures,program modules, or other data.

Example 1

The reagents in each test chamber, also referred to as a test well, caninclude all the reagents needed for evaluating one or more indices ofhemostasis.

Optionally the cartridge is a single use, disposable cartridge withpre-loaded lyophilized reagents. The cartridge can be used with wholeblood from a subject. The cartridge or assay components include thefollowing for fresh whole blood samples. Four separate wells containinglyophilized reagents to which 1.6 ml of fresh whole blood is added. Eachtest well utilizes around 300 μl of fresh whole blood along with thefollowing reagents:

TABLE 1 Test Well 1 Test Well 2 Test Well 3 Test Well 4 0.15 mg of 0.15mg of 0.3 U of recombinant kaolin kaolin thrombin tissue factor buffersand buffers and buffers and buffers and stabilizers stabilizersstabilizers stabilizers 0 μl of 2 mg/ml 12 μl of 2 mg/ml 12 μl of 2mg/ml 0 μl of 2 mg/ml abciximab abciximab abciximab abciximab

The devices systems and methods use the phenomenon of acoustic radiationforce to measure changes in mechanical properties (e.g. stiffness) of ablood sample during the processes of coagulation and fibrinolysis. Thesechanges are representative of the role of the four key components ofhemostasis: (i) plasma coagulation factors, (ii) platelets, (iii)fibrinogen, and (iv) fibrinolytic factors of the plasma. The basicapproach is shown in FIGS. 6A-C.

A series of N focused ultrasound pulses are sent into a blood sample atshort intervals ΔT (ΔT is on the order of microseconds), as shownschematically in panel A. Each pulse generates a small and localizedforce within the blood as acoustic energy is absorbed and reflectedduring propagation. This force, which is concentrated around the focusof the ultrasound beam, induces a small displacement within the bloodsample that depends upon the local mechanical properties. Thesedisplacements are on the order of 40 microns or less at the focus of theultrasound beam.

Each pulse also returns an echo, as a portion of its energy is reflectedfrom within the blood sample. Because the sample moves slightly from onepulse transmission to the next, the path length between the fixedultrasound emitter and any given region within the target increases withpulse number. This change in path length can be estimated fromdifferences in the arrival times of echoes from the same region. Theensemble of these delays forms a time-displacement curve that holdscombined information about viscoelastic properties of the sample. Thesetime-displacement curves are shown in FIG. 6B. These time-displacementcurves are measured every 6 seconds to fully characterize the dynamicsof coagulation and fibrinolysis, representing the entire hemostaticprocess.

When the blood sample is in a viscous fluid state, the application ofthe acoustic force generates large displacements. As coagulation isactivated and fibrinogen is cross-linked into fibrin strands, the samplebehaves as viscoelastic solid and the induced displacement reduce as thestiffness of the sample increases. The interaction of platelets and thefibrin mesh also further reduce the induced displacements as the clot'sstiffness increases. As the clot progresses into the phase offibrinolysis, the fibrin mesh is dissolved by the fibrinolytic enzymesand the sample returns to viscous fluid, exhibiting increasingdisplacements.

The evolution of the magnitude of the induced displacements over time istherefore directly related to the changes in mechanical properties ofthe blood sample during hemostasis. A curve obtained with this method isshown in FIG. 6. Functional data, which highlights the role ofcoagulation factors, platelets, fibrinogen, and fibrinolysis can beextracted from the curve, as labeled in the FIG. 6.

Acoustic radiation force results from the transfer of momentum thatoccurs when a propagating acoustic wave is either absorbed or reflected.This body force acts in the direction of the propagating wave, and canbe approximated by the following expression:

$\begin{matrix}{F = {\frac{2\alpha\left\langle {I(t)} \right\rangle}{c} = {\frac{2\alpha\;{PII}}{c}\frac{1}{\Delta\; T}}}} & (1)\end{matrix}$

where α [m−1] is the acoustic attenuation coefficient, c [m/s] is thespeed of sound, I(t) [W/m2] is the instantaneous intensity of theultrasound beam, PII is the pulse intensity integral, ΔT [s] is the timeinterval between successive ultrasound pulse transmissions, and < >indicates a time averaged quantity.

The acoustic energy used by the instrument to generate acousticradiation force is comparable with the acoustic energy typically usedfor common medical ultrasound procedures such as color Doppler imaging.The estimated maximum acoustic intensity is on the order of 2.5 W/cm2(time average), which results in a temperature increase of the bloodsample of 0.01° C. for each measurement ensemble (performed roughlyevery 6 seconds).

As the blood sample rapidly changes from viscous fluid to viscoelasticsolid during coagulation and back to viscous fluid after clot lysis, theapplied acoustic radiation force is adaptively changed to inducedisplacements above the noise threshold, but below levels that couldinduce mechanical disruption (typically below 40 microns).

The magnitude of the force is adjusted to follow the changes inmechanical properties of the blood sample by varying the time intervalΔT between successive pulses, as shown in equation 1. The maximumdisplacement induced during the (m−1)th acquisition is used to determinewhether the force should be increased or decreased for the mthacquisition, based on predetermined threshold values. This adaptiveprocess allows characterization of five orders of magnitude in stiffnesswithout generating high strain within the blood sample that could alterthe dynamics of coagulation and fibrinolysis.

As shown in equation (1), the applied acoustic radiation force changesas a function of acoustic attenuation and speed of sound, both of whichchange as a function of coagulation. The system uses the echoesreturning from within the cartridge to estimate changes in theseparameters and normalize the acoustic radiation force.

Acoustic radiation force is generated using conventional piezoelectricmaterials that act as acoustic emitters and receivers. These materialsdeform when a voltage is applied across them, and conversely generate avoltage when they are deformed. Similar to optics, an acoustic lens canbe placed in front of the piezoelectric material to focus acousticenergy on a single focal point.

In the example systems, method, and devices piezoelectric disks are usedthat have an active diameter of 7.5 mm. The acoustic lens is provided bythe curved shape of the disposable cartridge. Four disks are placed sideby side to send sound in the four test wells in a disposable. Thefrequency of vibration of these piezoelectric disks is centered at 10MHz, well within the range of frequencies used in conventionalultrasound imaging.

Ultrasound echo signals returning to the transducers from the bloodsamples are first filtered to remove electronic noise, digitized, andfurther processed within an embedded processor in the system. A flowchart of the data analysis steps performed by the system is shown inFIG. 7 where a test starts at block 700. Ultrasound pulses aretransmitted into a target sample in a test well at 702. Echoes arereceived, filtered and digitized at 704. After a short wait 706, steps702 to 704 can be repeated. A time delay estimation is applied at 708and an curve fitting at 710. The system then determines if enough datahas been acquired to estimated the desired indexes of hemostasis at 712.If there is enough data to estimate a hemostasis index, the hemostasisindex is estimated and 714 and displayed at 716. If at 712 it isdetermined that not enough data has been acquired to estimated ahemostasis index, the system determines if the test should be stopped at718 and, if so, an output summary is generated at 722. If the test is tocontinue, after a long wait 770, one or more steps 702-770 areoptionally repeated.

Time Delay Estimation

Once an ensemble of N pulses is sent into the blood sample and thereturning echoes are obtained, time delay estimation (TDE) is performedto estimate a local time-displacement curve, similar to that shown inFIG. 6B. TDE entails measuring the relative time shift from one receivedecho to the next; the known value of the speed of sound in blood allowsconversion of the time shifts into displacements. TDE is performedaround the focus of the ultrasound beam. This process is repeated every6 seconds (arbitrary fixed wait) to obtain time-displacement curvesthroughout the process of coagulation and fibrinolysis.

A variety of “off-the-shelf” algorithms are available to perform thisoperation. TDE is a common signal processing step in application fieldsranging from RADAR, SONAR, and medical ultrasound imaging (Doppler).

Curve Fitting

The viscoelastic properties of the blood sample during hemostasis aremodeled using a modified model consisting of the well-known Voigt-Kelvinmechanical model with the addition of inertia. While the dynamic changesin viscoelasticity of blood during hemostasis are certainly complex, themodified Voigt-Kelvin model is simple and robust, and it has been wellvalidated in the past.

Each time-displacement curve is fitted to the characteristic equation ofthe modified Voigt-Kelvin model to estimate a variety of parametersrelating to the viscoelastic properties of the sample. These parametersinclude relative elasticity, relative viscosity, time constant, andmaximum displacement. The mathematical expression of the equation ofmotion for the modified Voigt-Kelvin model is

$\begin{matrix}{{x(t)} = {{{- \frac{\xi + \sqrt{\xi^{2} - 1}}{2\sqrt{\xi^{2} - 1}}}{s \cdot {\mathbb{e}}^{{({{- \xi} + \sqrt{\xi^{2} - 1}})}\omega\; t}}} + {\frac{\xi - \sqrt{\xi^{2} - 1}}{2\sqrt{{\xi^{2} - 1}\;}}{s \cdot {\mathbb{e}}^{{({{- \xi} + \sqrt{\xi^{2} - 1}})}\omega\; t}}} + s}} & (2)\end{matrix}$

where ξ is the damping ratio, ω is the natural frequency, and s is thestatic sensitivity.

Among the parameters obtained by the curve fitting, the system uses theestimated displacement magnitude at 1 second as a qualitative measure ofthe stiffness of the sample. When blood is in viscous fluid state, thedisplacement at 1 second is high. As the blood coagulates thisdisplacement decreases proportionally to the generation of the fibrinmesh and activity of platelets. The value increases again during theprocess of fibrinolysis.

Estimate Indices of Hemostatic Function

The displacement values obtained at 1 second for each data acquisitionare compiled to form a curve showing relative stiffness as a function oftime (FIG. 6C). This curve, previously shown, fully characterizeshemostasis and can be further processed to estimate direct indices ofhemostatic function.

Indices of hemostasis are calculated by fitting a sigmoidal curve to thestiffness-time curve (FIG. 6C) and evaluating the first derivative ofthe curve. The times to clot TC1 and TC2 are calculated based on athreshold value of the derivative curve (20% of the minimum value), andare indicative of the beginning and ending phase of fibrinpolymerization. The clotting slope CFR is the maximum of the derivativecurve and is indicative of the rate of fibrin polymerization. Thestiffness S is estimated from the stiffness curve 3 minutes after TC2. Sdepends upon platelet function and the final stiffness of the fibrinnetwork. Identical methods and indices are calculated for thefibrinolytic process. In particular the times TL1 and TL2 can be definedto represent the initial and final phases of the fibrinolytic processand the consequent dissolution of the fibrin network (time to lysis).

A summary of the parameters generated for each test chamber is presentedin the table 2:

Parameter Information provided Dependent upon TC₁, TC₂ Measure initialand final Function of fibrinogen and fibrin formation other coagulationfactors S Fibrin and platelet activity Function of fibrin network andplatelet aggregation CFR Rate of fibrin polymerization Function offibrinogen and other coagulation factors TL₁, TL₂ Clot dissolvingprocess Function of fibrinolytic proteins of the plasma

In order to isolate the four main components of hemostasis, fourmeasurements are performed in parallel within the disposable cartridgeusing a combination of agonists and antagonists in each of four wells.The measurements in each well are combined to form indices of hemostasisas shown in the table 3:

Output Method Coagulation factors Time to clot TC₁ in well #1 Index(Intrinsic Pathway) Coagulation factors Time to clot TC₁ in well #4Index (Extrinsic Pathway) Platelets Index Stiffness S differentialbetween well #1 and well #2 Fibrinogen Index Stiffness S in well #3Fibrinolysis Index Time to lysis TL₁ in well #4

Many modifications and other embodiments of the invention set forthherein will come to mind to one skilled in the art to which thisinvention pertains having the benefit of the teachings presented in theforegoing description. Therefore, it is to be understood that theinvention is not to be limited to the specific embodiments disclosed andthat modifications and other embodiments are intended to be includedwithin the scope of the appended claims. Although specific terms areemployed herein, they are used in a generic and descriptive sense onlyand not for purposes of limitation.

What is claimed is:
 1. A device for evaluation of hemostasis, comprising: a plurality of test chambers each configured to receive blood of a test sample, each test chamber comprising a reagent or combination of reagents, wherein each chamber is configured to be interrogated to determine a hemostatic parameter of the blood received therein; a first chamber of the plurality comprising a first reagent or a first combination of reagents that interact with the blood received therein, wherein the first reagent, or a reagent included in the first combination of reagents, is an activator of coagulation; and a second chamber of the plurality comprising a second combination of reagents that interact with blood of the test sample received therein, the combination including an activator of coagulation and one or both of abciximab and cytochalasin D.
 2. The device of claim 1, wherein the first chamber comprises a first combination of reagents including one or more of kaolin, celite, glass, thrombin, ellagic acid, and tissue factor, and wherein the second chamber comprises a second combination of reagents including one or more of kaolin, celite, glass, thrombin, ellagic acid, and tissue factor. 